{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T06:54:17Z","timestamp":1769583257436,"version":"3.49.0"},"reference-count":35,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"ICMR"},{"name":"New Delhi"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Background: Hepatocellular carcinoma (HCC) is the second most common malignancy with increasing cancer deaths worldwide. HCC is mainly diagnosed at its advanced stage, and treatment with FDA-approved sorafenib, the multikinase inhibitor drug, is advised. Acquired resistance against sorafenib develops through several pathways involving hypoxia, autophagy, high glycolysis, or glutaminolysis. Small non-coding RNAs, similar to microRNAs (miRNAs), are also known to affect sorafenib resistance in HCC. However, there is a lack of information regarding the significance of differentially expressed miRNA (if any) on autophagy and glutamine regulation in sorafenib-resistant HCC. Methods: The expression of autophagy and glutaminolysis genes was checked in both parental and sorafenib resistant HepG2 cell lines by real-time PCR. MTT and Annexin\/PI assays were also performed in the presence of inhibitors such as chloroquine (autophagy inhibitor) and BPTES (glutaminolysis inhibitor). Next generation sequencing and in silico analysis were performed to select autophagy and glutamine addiction-specific microRNA. Selected miRNA were transfected into both HepG2 cells to examine its effect on autophagy and glutamine addiction in regulating sorafenib-resistant HCC. Results: Our in vitro study depicted a higher expression of genes encoding autophagy and glutaminolysis in sorafenib-resistant HepG2 cells. Moreover, inhibitors for autophagy (chloroquine) and glutaminolysis (BPTES) showed a diminished level of cell viability and augmentation in cell apoptosis of sorafenib-resistant HepG2 cells. NGS and real-time PCR demonstrated the downregulated expression of miR-23b-3p in sorafenib-resistant cells compared to parental cells. In silico analysis showed that miR-23b-3p specifically targeted autophagy through ATG12 and glutaminolysis through GLS1. In transfection assays, mimics of miR-23b-3p demonstrated reduced gene expression for both ATG12 and GLS1, decreased cell viability, and increased cell apoptosis of sorafenib-resistant HepG2 cells, whereas the antimiRs of miR-23b-3p demonstrated contrasting results. Conclusion: Our study highlights the cytoprotective role of autophagy and glutamine addiction modulated by miR-23b-3p (tumor suppressor), suggesting new approaches to curb sorafenib resistance in HCC.<\/jats:p>","DOI":"10.3390\/genes13081375","type":"journal-article","created":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T02:06:42Z","timestamp":1659319602000},"page":"1375","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["miR-23b-3p Modulating Cytoprotective Autophagy and Glutamine Addiction in Sorafenib Resistant HepG2, a Hepatocellular Carcinoma Cell Line"],"prefix":"10.3390","volume":"13","author":[{"given":"Ramanpreet","family":"Kaur","sequence":"first","affiliation":[{"name":"Department of Experimental Medicine and Biotechnology, Postgraduate Institute of Medical Education & Research (PGIMER), Chandigarh 160012, India"},{"name":"Department of Hepatology, Postgraduate Institute of Medical Education & Research (PGIMER), Chandigarh 160012, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shruthi","family":"Kanthaje","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine and Biotechnology, Postgraduate Institute of Medical Education & Research (PGIMER), Chandigarh 160012, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunil","family":"Taneja","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Postgraduate Institute of Medical Education & Research (PGIMER), Chandigarh 160012, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radha K.","family":"Dhiman","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Postgraduate Institute of Medical Education & Research (PGIMER), Chandigarh 160012, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8306-7558","authenticated-orcid":false,"given":"Anuradha","family":"Chakraborti","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine and Biotechnology, Postgraduate Institute of Medical Education & Research (PGIMER), Chandigarh 160012, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jhep.2017.03.011","article-title":"Global trends and predictions in hepatocellular carcinoma mortality","volume":"67","author":"Bertuccio","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.jceh.2014.05.013","article-title":"Epidemiology of hepatocellular carcinoma in India","volume":"4","author":"Acharya","year":"2014","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1046\/j.1440-1746.2001.02476.x","article-title":"Profile of hepatocellular carcinoma in India: An insight into the possible etiologic associations","volume":"16","author":"Sarin","year":"2001","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0076-6879(05)07047-3","article-title":"Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF\/MEK\/ERK pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature","volume":"407","author":"Adnane","year":"2006","journal-title":"Methods Enzymol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1517\/17425255.3.6.805","article-title":"Drug resistance in cancer\u2014Searching for mechanisms, markers and therapeutic agents","volume":"3","author":"Clynes","year":"2007","journal-title":"Expert. Opin. Drug Metab. Toxicol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"11851","DOI":"10.1158\/0008-5472.CAN-06-1377","article-title":"Sorafenib blocks the RAF\/MEK\/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC\/PRF\/5","volume":"66","author":"Liu","year":"2006","journal-title":"Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3350\/cmh.2019.0031","article-title":"Vimentin as a potential therapeutic target in sorafenib resistant HepG2, a HCC model cell line","volume":"26","author":"Makol","year":"2020","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/aps.2017.5","article-title":"New knowledge of the mechanisms of sorafenib resistance in liver cancer","volume":"38","author":"Zhu","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"102610","DOI":"10.1016\/j.ebiom.2019.102610","article-title":"The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma","volume":"51","author":"Xia","year":"2020","journal-title":"EBioMedicine"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e485","DOI":"10.1038\/cddis.2013.18","article-title":"Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells","volume":"4","author":"Tai","year":"2013","journal-title":"Cell Death Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ijc.26374","article-title":"Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma","volume":"131","author":"Shimizu","year":"2012","journal-title":"Int. J. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.3892\/ol.2017.6573","article-title":"Inhibition of autophagy potentiates the proliferation inhibition activity of microRNA-7 in human hepatocellular carcinoma cells","volume":"14","author":"Wang","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1158\/1535-7163.MCT-13-1043","article-title":"Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma","volume":"13","author":"Zhai","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1002\/hep.26224","article-title":"Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1\u03b1 inhibition in hepatocellular carcinoma","volume":"57","author":"Liang","year":"2013","journal-title":"Hepatology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13046-015-0221-y","article-title":"Metabolic reprogramming: The emerging concept and associated therapeutic strategies","volume":"34","author":"Yoshida","year":"2015","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1126\/science.122.3168.501","article-title":"Nutrition needs of mammalian cells in tissue culture","volume":"122","author":"Eagle","year":"1955","journal-title":"Science"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"7619","DOI":"10.18632\/oncotarget.3196","article-title":"Kidney-type glutaminase (GLS1) is a biomarker for pathologic diagnosis and prognosis of hepatocellular carcinoma","volume":"6","author":"Yu","year":"2015","journal-title":"Oncotarget"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1042\/BJ20070039","article-title":"Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulphide (BPTES)","volume":"406","author":"Robinson","year":"2007","journal-title":"Biochem. J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/hepr.12991","article-title":"Sorafenib response in hepatocellular carcinoma: MicroRNAs as tuning forks","volume":"48","author":"Kanthaje","year":"2018","journal-title":"Hepatol. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using realtime quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0022-1759(95)00072-I","article-title":"A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin, V","volume":"184","author":"Vermes","year":"1995","journal-title":"J. Immunol. Methods"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.molonc.2014.03.019","article-title":"Characterization of microRNA transcriptome in lung cancer by next-generation deep sequencing","volume":"8","author":"Ma","year":"2014","journal-title":"Mol. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2174\/156652411794859250","article-title":"Practical Aspects of microRNA Target Prediction","volume":"11","author":"Witkos","year":"2011","journal-title":"Curr. Mol. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"526","DOI":"10.4103\/ijc.IJC_373_17","article-title":"Advanced hepatocellular carcinoma: A regional cancer center experience of 48 cases","volume":"54","author":"Chaudhuri","year":"2017","journal-title":"Indian J. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1111\/j.1742-4658.2011.08271.x","article-title":"Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib--the role of extracellular signal-regulated kinase counteraction","volume":"278","author":"Manov","year":"2011","journal-title":"FEBS J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/cbin.11182","article-title":"miR-145 inhibits glutamine metabolism through c-myc\/GLS1 pathways in ovarian cancer cells","volume":"43","author":"Li","year":"2019","journal-title":"Cell Biol. Int."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1007\/s00726-014-1785-0","article-title":"L-Glutamine deprivation induces autophagy and alters the mTOR and MAPK signaling pathways in porcine intestinal epithelial cells","volume":"47","author":"Zhu","year":"2015","journal-title":"Amino Acids"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1002\/cam4.3020","article-title":"SNGH16 regulates cell autophagy to promote Sorafenib Resistance through suppressing miR-23b-3p via sponging EGR1 in hepatocellular carcinoma","volume":"9","author":"Jing","year":"2020","journal-title":"Cancer Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e1766","DOI":"10.1038\/cddis.2015.123","article-title":"miR-23b-3p regulates the chemoresistance of gastric cancer cells by targeting ATG12 and HMGB2","volume":"6","author":"An","year":"2015","journal-title":"Cell Death Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41419-019-1614-1","article-title":"miR-23b-3p suppressing PGC1\u03b1 promotes proliferation through reprogramming metabolism in osteosarcoma","volume":"10","author":"Zhu","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_34","first-page":"2813","article-title":"Downregulated miR-23b-3p expression acts as a predictor of hepatocellular carcinoma progression: A study based on public data and RT-qPCR verification","volume":"41","author":"He","year":"2018","journal-title":"Int. J. Mol. Med."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Manganelli, M., Grossi, I., Ferracin, M., Guerriero, P., Negrini, M., Ghidini, M., Senti, C., Ratti, M., Pizzo, C., and Passalacqua, R. (2021). Longitudinal Circulating Levels of miR-23b-3p, miR-126-3p and lncRNA GAS5 in HCC Patients Treated with Sorafenib. Biomedicines, 13.","DOI":"10.3390\/biomedicines9070813"}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/13\/8\/1375\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:37Z","timestamp":1760140837000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/13\/8\/1375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,1]]},"references-count":35,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["genes13081375"],"URL":"https:\/\/doi.org\/10.3390\/genes13081375","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,1]]}}}